10 June 2021 - The price of Yuhan's third generation epidermal growth factor receptor tyrosine kinase inhibitor for treating patients with non-small cell lung cancer, Leclaza (lazertinib), will be slightly lower than AstraZeneca's Tagrisso (osimertinib mesylate).

According to industry insiders, Yuhan has completed its drug price negotiation for Leclaza with the National Health Insurance Service on Monday and has set a drug price of 69,000 won/80 mg tablet. Considering that the drug has a recommended daily dose of 240 mg, patients will have to pay about 207,000 won/day.

Read Korea Biomedical Review article